GlassScriptPhysician profile
Amer A Saba
NPI 1508923582
$2,696.80
in general payments reported to CMS, 2019-2025
12 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $575 · 2021: $795 · 2022: $262 · 2023: $143 · 2024: $340 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $639.78 | 2021-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Smith+Nephew, INC. | $429.90 | 2020-2024 | Stravix |
| Baxter Healthcare | $267.30 | 2020-2024 | |
| Bard Peripheral Vascular, INC. | $217.73 | 2021 | |
| Exsomed Corporation | $208.20 | 2020 | |
| Allergan, INC. | $207.01 | 2019-2022 | |
| Access Pro Medical, LLC | $190.91 | 2025 | Matriderm |
| Innovation Technologies INC | $129.06 | 2020-2021 | |
| Mentor Worldwide LLC | $124.74 | 2021 | |
| Avita Medical Americas, LLC | $118.10 | 2024 | |
| Axogen | $89.94 | 2025 | |
| Biocircuit Technologies INC | $74.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Saba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.